Cholinergic deficits in Alzheimer’s disease

• Acetylcholine is a major neurotransmitter in the brain¹
• In patients with AD, cholinergic neurons are progressively lost, reducing levels of acetylcholine¹
• ChEIs target cholinesterase enzymes (AChE and BuChE) and inhibit the breakdown of acetylcholine.^1-3This increases the availability of acetylcholine at the cholinergic synapses.^1,2
• Currently available FDA-approved ChEIs for the treatment of mild, moderate and severe AD are donepezil, rivastigmine, and galantamine¹

Acess our Slide Deck on Treatment principles of Alzheimer’s disease (AD) and learn more about treatment with cholinesterase inhibitors.